Results 181 to 190 of about 81,953 (280)

Immune Effector Cell‐Associated Hematotoxicity With Secondary Myelofibrosis Following Idecabtagene‐Vicleucel for Multiple Myeloma, Comprehensively Treated With Autologous Hematopoietic Stem Cell Boosting

open access: yeseJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Pancytopenia accompanied by chimeric antigen receptor T cell (CAR‐T) therapy is termed immune effector cell‐associated hematopoietic toxicity (ICAHT), which is often sustained and refractory to supportive care. We report a case of a 52‐year‐old man with multiple myeloma who developed severe ICAHT with secondary myelofibrosis (sMF) after ...
Keishi Ogura   +9 more
wiley   +1 more source

Synthesis of sulfur-containing analogues of alpha GalNAc (Tn-antigen) and beta Gal1,3 alpha GalNAc (T-antigen)

open access: yes, 2002
A method for the preparation of thio-analogues of the T- and Tn-antigen was developed. Thus, starting from a known N-acetamido-glucoside derivative, the epidithio analogue of the Tn-antigen was accessible in a four-step reaction sequence.
Alexander G Hedenetz (16072772)   +6 more
core  

Natural History of Chronic Kidney Disease in Sickle Cell Disease

open access: yesAmerican Journal of Hematology, Volume 101, Issue 7, Page 1456-1477, July 2026.
ABSTRACT Kidney complications, referred to as nephropathy, develop early in sickle cell disease (SCD). In addition to its known morbidity, abundant data show that chronic kidney disease (CKD) is associated with an increased mortality risk in SCD. Increasing evidence suggests that the natural history of SCD nephropathy is progressive. Initial glomerular
Kenneth I. Ataga
wiley   +1 more source

Role of the Human ST6GalNAc-I and ST6GalNAc-II in the Synthesis of the Cancer-Associated Sialyl-Tn Antigen

open access: yes, 2004
The Sialyl-Tn antigen (Neu5Acalpha2-6GaINAc-O-Ser/Thr) is highly expressed in several human carcinomas and is associated with carcinoma aggressiveness and poor prognosis.
Harduin-Lepers, Anne   +12 more
core  

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial

open access: yesAmerican Journal of Hematology, Volume 101, Issue 7, Page 1494-1506, July 2026.
ABSTRACT Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health‐related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses versus placebo in patients with chronic ITP. ADVANCE SC, a Phase 3, multicenter, randomized, double‐blinded,
Nichola Cooper   +546 more
wiley   +1 more source

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience

open access: yesAmerican Journal of Hematology, Volume 101, Issue 7, Page 1597-1604, July 2026.
ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo   +38 more
wiley   +1 more source

Idecabtagene vicleucel and endogenous T‐cell phenotypes linked to progression‐free survival in relapsed multiple myeloma

open access: yesHemaSphere, Volume 10, Issue 7, July 2026.
Abstract Improved understanding of how chimeric antigen receptor (CAR) and endogenous T‐cell phenotypes associate with progression‐free survival (PFS) is needed to individualize and improve immunotherapy outcomes in multiple myeloma (MM). We characterized and investigated the prognostic value of immune dynamics defined with multidimensional and ...
Bruno Paiva   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy